Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...
For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...
When you have chronic obstructive pulmonary disease (COPD), many factors go into what type of treatment you’ll receive, including the severity of your condition and your symptoms. But one variable is ...
Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...
Verywell Health on MSN
Don’t combine these COPD medicines
Check this table to make sure you can use your COPD inhalers together Medically reviewed by Lindsay Cook, PharmD Some COPD inhalers should not be used together because they can cause dangerous side ...
Recent medical research reveals promising developments in the treatment of patients suffering from both diabetes and chronic obstructive pulmonary disease. The study, involving nearly 394,000 adults, ...
Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary ...
The U.S. Food and Drug Administration on Tuesday approved the first generic Symbicort drug used to treat asthma and chronic obstructive pulmonary disease (COPD), which are two common pulmonary health ...
The US Food and Drug Administration (FDA) on Thursday released a revised version of its draft guidance intended to help pharmaceutical companies develop products to treat the lung disease known as ...
Add Yahoo as a preferred source to see more of our stories on Google. AstraZeneca's IL-33 blocker AstraZeneca's first-in-class biologic, tozorakimab, has posted a double Phase III win in chronic ...
A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...
Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its experimental chronic obstructive pulmonary disease (COPD) treatment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results